Table 1.
Demographic characteristics of the study participants (total vaccinated cohort)
| V2 group N = 426 |
V1 group N = 431 |
V0 group* N = 143 |
|
|---|---|---|---|
| Age in months, mean (± SD) | 12.7 (1.7) | 12.6 (1.4) | 12.6 (1.2) |
| Female sex, n (%) | 198 (46.5) | 210 (48.7) | 69 (48.3) |
| Race, n (%) | |||
| ߓWhite/Caucasian | 423 (99.3) | 428 (99.3) | 143 (100) |
| ߓArabic/North African | 1 (0.2) | 0 (0.0) | 0 (0.0) |
| ߓEast/South East Asian | 2 (0.5) | 2 (0.5) | 0 (0.0) |
| ߓSouth Asian | 0 (0.0) | 1 (0.2) | 0 (0.0) |
| Contact with other children, n (%) | |||
| ߓAt least one sibling at home | 94 (22.1) | 98 (22.7) | 32 (22.4) |
| ߓAttending a day care center | 368 (86.4) | 376 (87.2) | 125 (87.4) |
| ߓAttending a childminder | 22 (5.2) | 23 (5.3) | 12 (8.4) |
| ߓAt least once a week at other places | 392 (92.0) | 399 (92.6) | 131 (91.6) |
N, total number of participants; n (%), number (percentage) of participants in a given category; SD, standard deviation; V0 group, control group receiving two doses of trivalent measles, mumps, and rubella vaccine (no varicella vaccine); V1 group, group receiving one dose of trivalent measles, mumps, and rubella vaccine followed by one dose of monovalent varicella vaccine; V2 group, group receiving two doses of tetravalent measles, mumps, rubella, and varicella vaccine.
* data for the V0 group (control group) were also published in Gillard 2021.45